• 1
    American Cancer Society. Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society; 2010.
  • 2
    Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371:1695-1709.
  • 3
    Pauloski BR, Logemann JA, Rademaker AW, et al. Speech and swallowing function after oral and oropharyngeal resections: 1-year follow-up. Head Neck. 1994;16:313-322.
  • 4
    Lefebvre JL, Rolland F, Tesselaar M, et al; EORTC Head and Neck Cancer Cooperative Group; EORTC Radiation Oncology Group. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009;101:142-152.
  • 5
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
  • 6
    Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol. 1999;17:1008-1019.
  • 7
    Efficace F, Bottomley A. Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. Eur J Cancer. 2002;38:1824-1831.
  • 8
    Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer. 2000;36:1796-1807.
  • 9
    Singer S, Arraras JI, Chie WC, Fisher SE, Galalae R, Hammerlid E, Nicolatou-Galitis O, Schmalz C, Verdonck-de Leeuw I, Gamper E, Keszte J, Hofmeister D. Performance of the EORTC questionnaire for the assessment of quality of life in head and neck cancer patients EORTC QLQ-H&N35: a methodological review. Qual Life Res 2012.
  • 10
    Dewolf L, Koller M, Velikova G, Johnson C, Scott N, Bottomley A, On Behalf of the EORTC Quality of Life Group. EORTC Translation Procedure Manual. Brussels, Belgium: EORTC; 2009.
  • 11
    Fayers P, Aaronson NK, Bjordal K, et al. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: EORTC; 2001.
  • 12
    Bottomley A, Flechtner H, Efficace F, et al; European Organisation for Research and Treatment of Cancer (EORTC) Data Center and Quality of Life Group. Health related quality of life outcomes in cancer clinical trials. Eur J Cancer. 2005;41:1697-1709.
  • 13
    Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139-144.
  • 14
    Scott NW, Fayers P, Bottomley A. EORTC QLQ-C30 Reference Values Manual. Brussels, Belgium: EORTC Quality of Life Group Publications; 2008.
  • 15
    van Herpen CML, Mauer ME, Mesia R, et al; EORTC Head and Neck Group. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer. 2010;103:1173-1181.
  • 16
    de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Long-term quality of life of patients with head and neck cancer. Laryngoscope. 2000;110:98-106.
  • 17
    Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007;25:2191-2197.
  • 18
    Pusic A, Liu JC, Chen CM, et al. A systematic review of patient-reported outcome measures in head and neck cancer surgery. Otolaryngol Head Neck Surg. 2007;136:525-535.
  • 19
    Bottomley A. The cancer patient and quality of life. Oncologist. 2002;7:120-125.